Loading clinical trials...

Study of Silodosin to Facilitate Passage of Urinary Stones | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Study of Silodosin to Facilitate Passage of Urinary Stones

A Double-Blind, Placebo-Controlled Study of Silodosin to Facilitate Urinary Stone Passage

NCT01144949•Watson Pharmaceuticals

Summary

The purpose of this study is to assess if patients treated with silodosin will have a higher spontaneous passage rate of their ureteral stone than those treated with placebo.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•At least 18 years of age or older
•Male or a non-pregnant, non-lactating female using adequate means of birth control, if not menopausal
•Have radiopaque unilateral ureteral calculus ≥4mm and ≤10mm in any location of the ureter

Exclusion Criteria

•Multiple ureteral calculi, or a solitary kidney, or refractory renal colic, or a non-opaque calculus, or active urinary tract infection, or severe hydronephrosis
•History of previous ureteral surgery or ureteral stricture on affected side
•History of any of the following conditions: myasthenia gravis, myopathy, spina bifida, spinal cord injury, autonomic nervous system disorder, fibromyalgia, breast cancer
•Moderate to severe renal impairment or severe liver insufficiency
•History of significant postural hypotension
•Is receiving medication(s) which preclude safe participation in the study or that may produce a confounding effect on the variables under study
•History of allergy to alpha-blockers or oxycodone

Locations (27)

Watson Investigational Site

Birmingham, Alabama, United States

Watson Investigational Site

Anchorage, Alaska, United States

Watson Investigative Site

Mission Hills, California, United States

Watson Investigational Site

Murrieta, California, United States

Watson Investigational Site

San Diego, California, United States

Watson Investigational Site

Daytona Beach, Florida, United States

Watson Investigational Site

Gainesville, Florida, United States

Watson Investigational Site

Orange City, Florida, United States

Watson Investigative Site

Overland Park, Kansas, United States

Watson Investigative Site

North Kansas City, Missouri, United States

Key Dates

Start Date

June 1, 2010

Primary Completion Date

July 1, 2012

Completion Date

July 1, 2012

Last Updated

August 11, 2014

Enrollment

239

ACTUAL participants

Conditions

Ureteral CalculiKidney StonesUrolithiasis

Interventions

silodosin

DRUG

placebo

DRUG

SGLT2i in Kidney Stones

NCT07055282

Kidney Stones

View study

RECRUITINGNA

Eye Gaze Guidance Evaluation in Phantoms

NCT07174479

Kidney Stones

View study

RECRUITINGNA

Evaluation of Quality of Life in Patients After Placement of a Modified Double J Ureteral Stent

NCT07275879

Ureteral Double-J Stent

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 11, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of Silodosin to Facilitate Passage of Urinary Stones

Inclusion Criteria

Exclusion Criteria

SGLT2i in Kidney Stones

Eye Gaze Guidance Evaluation in Phantoms

Evaluation of Quality of Life in Patients After Placement of a Modified Double J Ureteral Stent

Evaluation of Eye Gaze Sharing in the Operating Room

Intra-nasal Ketorolac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone Disease

Renal Stone Treatment Global Registry